Skip to main content

Advertisement

Table 2 Association of circulating matrix metalloproteinase (MMP)-9 concentrations with laboratory and clinical variables in patients (n = 35) with systemic sclerosis

From: Elevated matrix metalloproteinase-9 in patients with systemic sclerosis

  MMP-9 (ng/ml)a
Variable Variable present (%)b Variable absent
Modified Rodnan score >20 388 ± 29 (51)* 248 ± 38*
Esophageal involvementc 342 ± 33 (63) 304 ± 41
Interstitial lung diseased 321 ± 32 (60) 335 ± 41
Decrease of DLCO (<70%)e 350 ± 42 (43) 314 ± 34
Digital ulcer 364 ± 32 (43) 260 ± 35
Arthritis 333 ± 58 (14) 333 ± 28
Sicca syndrome 358 ± 40 (31) 320 ± 31
Antibodies to Scl-70f 348 ± 36 (37) 323 ± 45
Antibodies to centromere-Bf 288 ± 34 (37) 370 ± 39
  1. aConcentrations are presented as mean ± standard error of the mean. bPercentage of patients in whom the variable was clearly present; all other patients are included in the 'Variable absent' group. cDetermined by endoscopy and esophageal manometry. dEvaluated by chest x-ray and/or high-resolution computerized tomography, if necessary. eAbnormal diffusion capacity (DLCO, diffusion of carbon monoxide in the lung) on pulmonary function test was defined as below 70% of that in healthy controls. fMeasured by ELISA. *P = 0.006 in a comparison of the two groups (Mann–Whitney rank sum test). All other differences were not significant.